Clinical Trials Logo

Glabellar Frown Lines clinical trials

View clinical trials related to Glabellar Frown Lines.

Filter by:

NCT ID: NCT01391299 Completed - Clinical trials for Glabellar Frown Lines

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines

Start date: June 1, 2011
Phase: N/A
Study type: Interventional

This study evaluated the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of forehead lines (facial rhytides) when also administered to frown lines (glabellar rhytides).

NCT ID: NCT01333397 Completed - Clinical trials for Glabellar Frown Lines

Safety and Efficacy Study of Dysport RU and Glabellar Lines

Start date: March 2011
Phase: Phase 2
Study type: Interventional

The primary objective is to assess the dose response versus placebo of a single treatment of Dysport RU (Dysport RU, Ready to Use, for injection), for the improvement in appearance of moderate to severe glabellar lines at maximum frown.

NCT ID: NCT00777803 Completed - Clinical trials for Glabellar Frown Lines

NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines

Head2Head
Start date: November 2008
Phase: Phase 3
Study type: Interventional

NT 201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), is a Botulinum toxin type A preparation free of complexing proteins (150 kiloDalton). Injected into the muscle, NT201 causes a reversible local relaxation of the injected muscle. Botulinum toxin type A is used for aesthetic treatment of mimic wrinkles and in the therapy of neurologic diseases. This study will investigate the safety and efficacy (non-inferiority) of NT 201 in comparison with OnabotulinumtoxinA (Vistabel®) in the treatment of glabellar frown lines.

NCT ID: NCT00430963 Completed - Clinical trials for Glabellar Frown Lines

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

Start date: October 2006
Phase: Phase 3
Study type: Interventional

IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free of complexing proteins, i.e. free of proteins other than the active toxin. Injected into the muscle, IncobotulinumtoxinA (Xeomin) causes local weakening. Botulinum toxin type A is widely used for aesthetic treatment of facial lines. This study investigated the efficacy and safety of IncobotulinumtoxinA (Xeomin) in the treatment of glabellar frown lines compared to placebo. The study consisted of a Main Period and an Open-Label Extension [OLEX] Period of 120 days each.

NCT ID: NCT00430586 Completed - Clinical trials for Glabellar Frown Lines

Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines

Start date: November 2006
Phase: Phase 2
Study type: Interventional

NT 201 is a botulinum toxin type A preparation free of complexing proteins, i.e. free of proteins other than the active toxin. Injected into the muscle, NT 201 causes local weakening to full paralysis depending on the administered dose. Botulinum toxin type A is widely used for aesthetic treatment of facial lines. This study will determine the optimal dose of NT 201 in the treatment of glabellar frown lines.